This question tests chronic lung disease management skills, particularly the application of clinical guidelines in decision-making for smoking cessation in COPD. Chronic lung disease management involves assessing symptom severity, optimizing treatment regimens, and coordinating care. Key principles include recognizing exacerbations, adjusting medications appropriately, and planning follow-ups. In this vignette, the patient's ongoing smoking and exacerbations indicate a key modifiable risk. The correct choice, 'Provide smoking cessation counseling and offer pharmacotherapy support', aligns with current guidelines for managing COPD by reducing progression and exacerbations. The distractor 'Recommend doubling ALBUTEROL use daily to prevent attacks' is incorrect as it does not address the root cause, a common oversight in symptom management. Teaching strategies include reinforcing the importance of guideline-based therapy and the recognition of symptom patterns. Encourage students to differentiate between acute and chronic management needs and to prioritize interventions that modify disease progression.

This question tests chronic lung disease management skills, particularly the application of clinical guidelines in decision-making for asthma action plans. Chronic lung disease management involves assessing symptom severity, optimizing treatment regimens, and coordinating care. Key principles include recognizing exacerbations, adjusting medications appropriately, and planning follow-ups. In this vignette, the patient's peak flow drops and triggers indicate a need for self-management education. The correct choice, 'Use peak flow zones to guide step-up therapy and seek urgent care if in red zone', aligns with current guidelines for managing asthma by empowering patient response. The distractor 'Ignore peak flows and adjust medications only at annual visits' is incorrect as it delays intervention, a common oversight in monitoring. Teaching strategies include reinforcing the importance of guideline-based therapy and the recognition of symptom patterns. Encourage students to differentiate between acute and chronic management needs and to prioritize interventions that modify disease progression.

When you encounter a patient with combined pulmonary fibrosis and emphysema (CPFE), remember that addressing modifiable risk factors takes priority over symptomatic treatments. This case presents the classic CPFE pattern: upper lobe emphysema with lower lobe fibrosis in a heavy smoker, plus the characteristic severely reduced DLCO that's disproportionate to the mild airflow obstruction.

Answer D is correct because smoking cessation is the single most important intervention for CPFE patients. Continued smoking accelerates both emphysematous destruction and fibrotic progression, making it the primary modifiable factor. The 35-pack-year history indicates significant ongoing exposure that must be addressed immediately to prevent further lung damage.

Answer A is premature - while nintedanib may slow fibrotic progression, initiating antifibrotic therapy without first addressing the primary cause (smoking) is less effective and not the initial priority.

Answer B misses the point - though bronchodilators help with airflow obstruction, they don't address the underlying disease progression. The FEV1/FVC of 0.65 shows only moderate obstruction, making this less urgent than smoking cessation.

Answer C is inappropriate - high-dose corticosteroids are generally contraindicated in CPFE as they may worsen the emphysematous component and don't improve outcomes in established pulmonary fibrosis.

Study tip: In CPFE cases on Step 3, always prioritize smoking cessation over symptomatic treatments. Look for the combination of upper lobe emphysema, lower lobe fibrosis, and disproportionately reduced DLCO - this pattern signals that addressing smoking takes precedence over specific therapies.

When you encounter a patient with features of both asthma and COPD, you're dealing with asthma-COPD overlap (ACO), which requires specific therapeutic considerations. This patient shows classic ACO features: significant smoking history (COPD risk), childhood allergies and reversible airflow obstruction (asthma features), plus elevated eosinophils suggesting type-2 inflammation.

The key principle in ACO management is that these patients have underlying airway inflammation that requires anti-inflammatory treatment, unlike pure COPD where bronchodilators alone may suffice initially. The significant bronchodilator response (15% and 300 mL improvement) and eosinophilia (>300 cells/µL) strongly indicate a need for inhaled corticosteroids.

Choice A is correct because ICS/LABA combination therapy addresses both the inflammatory component (ICS) and provides bronchodilation (LABA). Current guidelines recommend ICS-containing regimens as first-line therapy for ACO patients, particularly those with eosinophilia.

Choice B (LABA monotherapy) is inappropriate and potentially dangerous, as LABA without ICS can increase mortality risk in asthma patients. Choice C (LAMA alone) provides bronchodilation but ignores the significant inflammatory component evidenced by the eosinophilia and reversibility. Choice D (LABA/LAMA) offers dual bronchodilation but lacks anti-inflammatory therapy, missing the key pathophysiologic driver in this patient.

Remember: ACO patients always need anti-inflammatory therapy upfront. When you see reversible airflow obstruction plus eosinophilia in a patient with smoking history, think ICS-containing combinations, not bronchodilator monotherapy.

This patient has severe COPD with a chronic bronchitis phenotype (daily productive cough) and continues to have frequent exacerbations despite optimal triple therapy (ICS/LAMA/LABA). According to GOLD guidelines, for patients with an FEV1 < 50% and chronic bronchitis, adding roflumilast, a phosphodiesterase-4 inhibitor, is recommended to reduce exacerbations. His eosinophil count is < 300 cells/µL, making ICS benefit less certain, but he is already on it. Roflumilast is the most appropriate next step for his specific phenotype.

According to asthma management guidelines (e.g., GINA), when a patient's asthma has been well-controlled for at least 3 months, step-down therapy should be considered to find the minimum effective dose to maintain control and reduce long-term side effects. The most appropriate step-down for a patient on a medium-dose ICS/LABA is to reduce it to a low-dose ICS/LABA. Discontinuing the controller medication entirely is inappropriate, and switching to ICS alone removes the LABA that may be contributing to control. Continuing the current dose without attempting a step-down is not optimal.

For patients with non-CF bronchiectasis and frequent exacerbations (≥3 per year) who are chronically colonized with Pseudomonas aeruginosa, guidelines recommend long-term therapy with an inhaled antibiotic such as tobramycin or colistin, often in 28-day on/off cycles. This has been shown to reduce exacerbation frequency and improve quality of life. Long-term macrolide therapy (azithromycin) is an option for patients without Pseudomonas colonization or those who cannot tolerate inhaled antibiotics. Rotating oral antibiotics have a limited evidence base, and while hypertonic saline can aid mucus clearance, inhaled antibiotics are the specific intervention for suppressing chronic infection and reducing exacerbations in this context.

The criteria for continuous long-term oxygen therapy in stable COPD patients include a resting partial pressure of arterial oxygen (PaO2) ≤ 55 mm Hg or an arterial oxygen saturation (SaO2) ≤ 88%. A PaO2 of 54 mm Hg (and SaO2 of 87%) meets this criterion. A PaO2 between 56 and 59 mm Hg or an SaO2 of 89% only qualifies a patient if there is evidence of end-organ damage, such as cor pulmonale (pulmonary hypertension, peripheral edema) or erythrocytosis (hematocrit > 55%). Oxygen desaturation only during exercise qualifies a patient for ambulatory oxygen, not continuous therapy.

This patient has WHO Group 3 pulmonary hypertension, which is PH due to chronic lung disease and/or hypoxia. The cornerstone of management for this group is to treat and optimize the underlying lung disease and correct hypoxemia with supplemental oxygen. While targeted pulmonary arterial hypertension (PAH) therapies like prostacyclin analogs or PDE-5 inhibitors are used in Group 1 PAH, their use in Group 3 is controversial and not first-line, as they can worsen ventilation-perfusion mismatch. Pulmonary thromboendarterectomy is the treatment for Group 4 PH (CTEPH), not Group 3.

This patient is having a mild CF pulmonary exacerbation, indicated by increased symptoms and a drop in FEV1 of less than 10% from baseline. For mild exacerbations in patients who can be managed as outpatients, oral antibiotics are appropriate. The choice of antibiotic should be guided by previous sputum cultures. Since his last culture grew Staphylococcus aureus, an antibiotic with activity against it, such as trimethoprim-sulfamethoxazole, is a suitable choice. Ciprofloxacin is primarily used for Pseudomonas coverage. Hospitalization for IV antibiotics is reserved for more severe exacerbations. Observation alone is insufficient given the objective decline in lung function.